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The human body has a great ability to remodel and regenerate small
defects. Severe injuries or large defects due to disease or congenital ab-
normalities are considerablymore difﬁcult or impossible for the body to
heal on its own. Therefore, regenerative strategies, including stem cell-
based therapies and tissue engineering applications, are being devel-
oped with the aim to replace, remodel, regenerate or support damagedthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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healing capacity. The tissue engineering approach includes the isolation
and culture of speciﬁc cell types in either static or bioreactor-controlled
dynamic conditions, the generation of artiﬁcial tissues by seeding these
cells onto three-dimensional (3D) scaffolds, and the implantation of the
engineered tissue into the patient [1–3].
Proper design of 3D scaffolds is just as important as careful cell type
selectionwhen developing new tissues. The scaffolds are typicallymade
of degradable or non-degradable biomaterials and can serve as cell or
drug carriers. Different biomaterials can be used in order to generate
3D scaffolds. Syntheticmaterials such as poly-L-lactide [4], polyurethane
[5] or polyethylene glycol [6] have been used to achieve excellent
mechanical support and scaffold stability. Natural materials, which can
be structurally weaker when compared to synthetic materials [7], have
been successfully used as biomaterials to provide biological cues to
cells and surrounding tissues. For example, alginate [8] or chitosan [9]
belong to this class of biomaterials, but also extracellular matrix (ECM)
or ECM components [10–12] have been used as natural biomaterials.
In this review, we will discuss the use of ECM and ECM-like mate-
rials, or ECM-synthetic polymer hybrids, as biomaterials in the ﬁeld of
regenerative medicine, including cell and cancer drug delivery, and
their use as vehicles for cancer therapy.
2. ECM and ECM-like materials as implants
The ECM is the natural 3D microenvironment in which cells reside.
It is composed of ﬁber-forming proteins such as collagens and elastic
ﬁbers, as well as non-ﬁber-forming proteins like proteoglycans, glycos-
aminoglycans and soluble factors [13–15]. The ECM is highly hetero-
genic and its composition varies from tissue to tissue. Organ-speciﬁc
cells secrete, assemble and constantly remodel the ECM. Cells bind via
cell surface receptors to the ECM, whereby cellular responses such as
migration, proliferation and differentiation become activated [14]. Ac-
cordingly, the ECM, its components, structural organization and biome-
chanics, are highly interesting for biomaterials design and fabrication,
especially when aiming for implant or test system generation.
2.1. Decellularized materials
First reported in 1948, decellularization aims to isolate the ECM
from its inhabiting cells [16]. In this very early research, Poel et al.
minced muscle tissue in a wooden box at−70 °C until the tissue was
completely homogenized. After centrifugation, they found that some
of the cells had been removed from the tissue, and thus began the
science of decellularization. One of the ﬁrst reports of developing
decellularized tissue for a therapy was in 1991 where Nrejci et al. com-
bined decellularized human skin, human keratinocytes and ﬁbroblasts
to create a reconstituted skin that was transplanted into a mouse
model. They showed that the acellular dermis supported keratinocyte
attachment, stratiﬁcation, growth, and differentiation in vivo [17]. In
1995, Badylak et al. ﬁrst used xenogenic decellularized small intestinal
submucosa (SIS) ECM as a biomaterial for Achilles tendon repair [18].
The group demonstrated that the SIS-repaired tendons were stronger
than controls and that the SIS degraded within the ﬁrst 8 weeks post
surgery, suggesting that the body began to degrade and replace the
SIS with its natural connective tissue in a normal ECM turnover process.
The late 90s saw the development of decellularized tissues and organs
as implants in the ﬁelds of dermal, heart valve, vascular and esophageal
tissue engineering [19–23].
Decellularization aims to remove cells from their ECM and thereby
removing potential antigens that can cause an inﬂammatory response
or immune-mediated implant rejection [23]. Keane et al. nicely summa-
rized possible events that cause inﬂammation; such as ineffective
decellularization, change of ECM ﬁber structure, residual detergent or
remaining endotoxins [24]. Many different approaches have been used
to extract cells from the ECM [24–30]. Since cell and matrix density,morphology and thickness vary from organ to organ, the optimal meth-
od for decellularization is highly dependent on the type of tissue [24].
Physical treatments such as agitation, sonication, mechanical pressure,
or freeze-thawing procedures, in order to disrupt the cell membrane
are commonly combined with extensive washing steps and further
chemical processing with ionic solutions and various detergents [23].
Enzymatic treatment using trypsin, dispase, esterases or nucleases has
also been employed to remove cells from tissues [30]. Most of the men-
tioned decellularization techniques have only been assessed in vitro;
however, methods like hydrostatic pressure application, enzymatic
and detergent treatments are the standard protocols used in daily lab
activities and have also been investigated in vivo [27,29,31–34]. Cur-
rently published studies and clinical trials strongly focus on chemical
detergents, particularly regarding heart valve [34,35], tracheal [32,36]
and uterine tissue [37]. After the cellular components are removed, a
3D ﬁbrous and porous ECM structure, mainly composed of collagen ﬁ-
bers, can be maintained [24,38]. The main beneﬁt of a decellularized
organ or tissue is the presence of 3D ﬁbrous and porous topographies,
as well as macrostructures like the vasculature [24,28]. However, ultra-
structural analyses have shown that one major disadvantage of this
method is that the process of decellularization potentially damages
crucial structural tissue elements such as elastic ﬁbers [26]. Moreover,
proteoglycans (PGs) and glycosaminoglycans (GAGs), which connect
cells to collagen bundles or elastic ﬁbers and induce a variety of cellular
responses, are mainly depleted from decellularized tissues [26]. Since
GAGs bind and store high amounts of water, they enable matrices
formed by these molecules to withstand high compressive forces [14].
Thus, the loss of PGs and GAGs might have an important impact on
ECM structure and integrity, which ultimately translates to implant per-
formance and durability. Bioreactor systems have been developed to
instruct reseeded cells to recover GAGs lost due to decellularization
[39], although, as shown in a recent study, the body may be the ideal
bioreactor for the recellularization, vascularization and personalization
of decellularized constructs. For example, Delaere et al. used the body
as a bioreactor to condition a native decellularized trachea within the
forearm of an implant recipient in an attempt to personalize the con-
struct with the patient's own ECM proteins [40].
Perfusion decellularization techniques have been proposed as a
method to manufacture whole organ scaffolds for in vitro implant
generation [41]. First used in 2003, Hopper et al. decellularized human
placenta as a potential vascularized scaffold for large tissue engineered
implants. Large tissues require their own vasculature due to increased
tissue thickness where diffusion does not provide the proper oxygen
and nutrients for cells [42]. One of the most high proﬁle examples
of this was the perfused decellularization and reseeding of a whole
human heart. Here, the majority of cells were removed from a whole
human heart within 4 to 8 days [43]. Afterwards, the decellularized
heart scaffolds were reseeded within 21 days using cardiac progenitor
cells (CPCs), mesenchymal stem cells (MSCs), HL-1 cardiomyocytes
and human umbilical vein endothelial cells (HUVECs). Interestingly,
mature calcium dynamics and electrical coupling were detected in
the reseeded heart, and a pumping force of approximately 25% of a
fetal heart was detectable [43]. In another study, Hill et al. described a
method to decellularize lungs using a bioreactor [44]. The lungs were
decellularized by perfusing a hypertonic detergent solution for 2 to
3 h at 37 °C. In this study, the authors intensely analyzed and quantiﬁed
the remaining ECM proteins and could demonstrate that the acellular
lung scaffolds were predominantly composed of structural collagens
[44]. Other organs such as the liverwere also successfully decellularized
and implanted into mice [33,45]. In the ﬁeld of pediatric oncology,
decellularized ovaries were utilized to recapitulate a native endocrine
function with the aim to induce puberty after chemotherapy [46].
Decellularized tissues and organs have been brought to market and
seen a number of clinical successes. The technique of removing cells
andmaintaining the 3D ECM construct has already been transferred to-
wards clinical trials [35,47]. Alloderm® (by BioHorizons, Birmingham,
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and has since been used for burn therapy [49], plastic surgery [50]
and hernia repair [51]. Furthermore, an early report on implanted
decellularized pulmonary heart valve homografts showed promising
results in patients regarding durability [35]. Decellularized bone
allografts have been very successful on the market and represent a
majority of bone grafts as access to autograft material is limited [52].
Particularly impressive was the success of Mase et al. in the clinical ap-
plication of a decellularized scaffold in a large quadriceps defect caused
by an explosive device. In this study, a 19-year-old marine was treated
after 3 years of unsuccessful physical therapy with a multi-layered scaf-
fold composed of ECM derived from porcine SIS. Four months post sur-
gery, the patient showed remarkable gains in isokinetic performance,
most likely the result of new tissue that had formed at the implant
site [53].
Despite the success of decellularized tissues in the clinical setting,
the ﬁeld has been involved in a number of controversies. The ﬁrst
decellularized porcine heart valves introduced in Europe, Synergraft®
(Cryolife Inc., Kennesaw, GA, USA), were implanted into 4 pediatric
patients in 2001 — two were homograft (donor organ) replacements
and two as part of a Ross operation (replacement of the aortic valve
with the patient's own pulmonary valve, and implantation of a substi-
tute in the pulmonary position) [54]. Despite normal recovery and
valve function post-surgery, 3 of the 4 children died due to valve failure
[54]. Two children suddenly died at 6 weeks and 1 year after implan-
tation due to severely degenerated Synergraft® valves. The third
child died at day 7 due to a Synergraft® rupture. The fourth valve was
explanted 2 days after implantation [54]. Analyses showed severe
inﬂammation in all valves, which led to failure of the day 7-explant,
and degeneration of the valve leaﬂets and walls in the 6 week and
1 year explants. Histological analysis of the Synergraft® valves also
showed an incomplete decellularization of the valves and calciﬁed de-
posits [54]. The tragic results of this study were the ﬁrst warning of
the dangers of using decellularized tissues, particularly when not prop-
erly processed. To ensure that this study remains a single case, non-
invasive pre-implantation quality control must be implemented. New,
non-invasive and potentially marker-free technologies for quality
assessment are essential in order to exclude implant contamination
with endotoxins and cellular residues. Multiphoton imaging is a well-
established method for the non-invasive analysis of tissue structure
post-decellularization or cryopreservation [55]. Other technologies
such as Raman microspectroscopy have recently been established to
monitor the quality of collagen bundles [56], elastin-containing ﬁbers
in heart valve leaﬂets [57], and proteoglycans [58]. Furthermore, the
clinical and scientiﬁc community must develop a greater appreciation
of the importance of ECM integrity in transplants and implants. Our
group previously demonstrated the effect of cardiomyopathy on heart
valve leaﬂet ECM integrity [59]. Despite this evidence, the European
community still permits the use of heart valves from donors suffering
from cardiomyopathy, in comparison to the US, where such transplants
are not allowed. It is our opinion that the impact of ECMdamage as a re-
sult of decellularization must be further investigated in regards to in-
ﬂammatory and immune response. For scientists working in the ﬁeld
of decellularization, new protocols that result in tissuewith amore con-
sistent ECM integrity are of the upmost importance because tissue stan-
dardizationwill enable the optimization of clinical protocols, whichwill
result in better patient outcomes.
The ﬁeld of decellularized trachea tissue engineering has had a
number of high proﬁle clinical successes. Macchiarini et al. successfully
transplanted a decellularized human donor trachea, reseeded with the
patient's chondrocytes and epithelial cells, into a 30-year old female
patient with end-stage bronchomalacia [60]. The patient was not
given immunosuppressive treatment and showed no signs of rejection
3 months after transplantation [60]. However, 5-year follow-up studies
showed that the decellularized transplant developed cicatricial stenosis
after the ﬁrst year, which required repeated endoluminal stenting[32]. The decellularized trachea itself appeared normal, completely
recellularized, well-vascularized, and had normal ciliary function and
mucus clearance [32].
In summary, theﬁeld of decellularized tissues is amaturing ﬁeld that
has seen both clinical success and failure. Major shortcomings thatmust
be addressed are the standardization of the decellularization process,
and implementation of reliable transplants and implant quality assess-
ment strategies. For example, it had been shown that tissues taken
from one or multiple donors that were decellularized by the same pro-
tocol showed signiﬁcantly different ECM compositions after processing
[54,61]. Despite the current hurdles, improvement of the efﬁciency and
effectiveness of the decellularization process may translate into more
clinical applications. However, the question of whether an unstandard-
ized decellularized tissue is “good enough” for clinical practice or if
regulatory agencies will soon require more deﬁned transplants or
scaffolds for implants remains to be answered. It is our opinion that
the ever more stringent Advanced Therapy Medicinal Product (ATMP)
regulations will require deﬁned implants that can be produced in an
upscalable and standardized method.
2.2. ECM proteins
There are many proteins in various sizes present in the ECM. Each
protein has a unique impact on cell behavior; therefore, using these pro-
teins as biomaterials for regenerative medicine applications potentially
enables the generation of functional scaffolds. The choice of the protein
or the combination of different proteins depends on the target applica-
tion and the desired effect. There are many options to acquire these
molecules. A common way to obtain native proteins is to isolate them
from human or animal tissues [62]; however, the predominant method
for biopharmaceutical production is the secretion of recombinant pro-
teins utilizing Chinese hamster ovary cells [63]. Furthermore, so-called
artiﬁcial or ECM-like proteins are of great interest in biomaterial scaffold
production. These molecules can be synthetically generated and are
comparable to full-length proteins [64]. They can solely contain a de-
ﬁned molecular weight and can have a speciﬁc sequence [64,65].
The following sections focus on methods and techniques to convert
ECM and ECM-like proteins to highly functional biomaterial scaffolds.
2.2.1. Coating
Surface modiﬁcations play an important role in tissue engineering
and regenerative medicine applications as they enhance cell adhesion
and potentially improve biocompatibility [66]. A simple way to attach
ECM components to the surface of a polymeric substrate is via coating,
which is a nonspeciﬁc physical adsorption on a surface [66]. The deliv-
ery of immobilized bioactive molecules is an attractive method to sup-
port tissue regeneration. For example, Ma et al. used this technique to
generate a drug release system using dextran sirolimus hybrid coatings
[67]. The authors demonstrated an excellent drug release proﬁle and an
improved biocompatibility of coated cardiovascular stents [67]. ECM
proteins have been successfully used to impact cell behavior. For exam-
ple, the basement membrane protein collagen type IV was previously
applied on surfaces as a coating. Here, the authors impressively demon-
strated that collagen type IV coatings allow induced pluripotent stem
(iPS) cells to differentiate into functional cells of the cardiovascular and
hematopoietic lineage [68]. In another study, a hybrid of ﬁbronectin and
gelatinwas used as a coating to improve bladder smoothmuscle cell ad-
hesion and proliferation [66]. The authors prepared electrospun poly(-
carbonate-urea) urethane (PCUU) scaffolds and compared ﬁbronectin-
gelatin coated PCUU with the uncoated PCUU specimen [66]. Further-
more, a mixture of collagen type I and chondroitin sulfate was attached
onto highly porous poly-ε-caprolactone (PCL) scaffolds to permit cell in-
ﬁltration [69]. As a result, the authors obtained new skull bone forma-
tion, to which they referred to as “ECM-inspired bone formation” [69].
Compared to covalent immobilization, the binding strength by physical
adsorption is lower and represents therefore a limitation when aiming
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seen as positive for drug releasing systems, since physically adsorped
ECMmolecules or drugs can be easily released to the surrounding tissue
after implantation. This phenomenonmakes coating a cost-efﬁcient and
highly attractivemethod to enable drug or ECMdelivery. Coating proce-
dures that can be applied right before implantation are, in our opinion,
more favorable than coatings applied early in the production process.
This allows the application of patient-speciﬁc dosages, better scalability
and reduces the need to store ECM-containing products thatmay have a
short half-life. In addition, it is advantageous that coating techniques
can be performed in aqueous solutions. In alcoholic solutions for exam-
ple, it has to be considered that alterations of protein structure and func-
tion occur [70]. Coating techniques are predominantly used in
laboratory setups. A few clinical approaches are documented, where,
for example, silver coating was used to avoid bacterial adhesion [71].Fig. 1. The electrospinning process. (A) Photograph showing the nozzle, where the polymer so
due to the electrical ﬁeld. As a result of the electrical ﬁeld, a ﬁber forms and travels in spinningm
(white) [4]. (C) A scanning electron microscopic image of an electrospun scaffold, showing ran2.2.2. Electrospinning
Electrospinning is an attractive method to generate ﬁbrous and
porous matrices with a high surface area for regenerative medicine
applications. Varying matrix properties, such as ﬁber and pore sizes,
enable the control of cellular responses including migration, prolifera-
tion and progenitor cell differentiation [72]. The basic experimental
set up for electrospinning includes a syringe, which is connected to a sy-
ringe pump, a conductive ﬂat or rotating electrode, also known as the
collector, and a high voltage power supply [73]. The polymer solution
is pumped through the syringe and forms a droplet on the needle
tip. By applying high voltage, the droplet adopts a conical shape, and
as soon as the electrical ﬁeld strength exceeds the surface tension, a
thin ﬁber develops (Fig. 1A). Due to equal charges, instabilities occur
and the ﬁber travels in spinning motions to the collector, the solvent
evaporates and a solid ﬁbrous network is generated (Fig. 1B) [74,75].lution is pumped through. A droplet forms on the nozzle tip, which adopts a conical shape
otions to the collector. (B) A valve-shaped copper collector with deposited polymer ﬁbers
domly oriented ﬁbers.
Fig. 2.Bioprinting technique. Bioprinting ofmethacrylated gelatinwith chondrocytes. Pat-
terns of viable chondrocytes are visualized in green.
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ed. Therefore, it is possible to spin ﬂat sheets, tubes or even the shape of
a heart valve (Fig. 1C). Today, there are various methods described to
electrospin synthetic polymers from different solvents [4,75–79]. One
of the ﬁrst examples of electrospinning ECM proteins was performed
by the Chaikof groupwhere they spun a 1wt% solution of type I collagen
with polyethylene oxide to create a collagen mesh [80]. Fourteen years
after the ﬁrst ECM scaffoldswere spun, groups have electrospun natural
decellularized ECM [81] or ECM components such as collagen blends
[82], hyaluronan [12] or proteoglycans [76]. Rao et al. used coaxial
electrospinning to create an in vitro model of brain white matter to
study themigration ofmalignant brain tumors. In this study, they tested
hyaluronic acid, collagen, and Matrigel, an extract of the Engelbreth-
Holm-Swarm EHS mouse tumor, in the outer shell of the nanoﬁbers to
analyze the effects of different proteins on cell migration [83].
Electrospun scaffolds can be layered using multiple methods. Recently,
Huang et al. used positively charged chitosan and negatively charged
collagen type 1 to create a layered scaffold to promote wound healing
[84]. An overview of electrospun ECM components or hybrids with syn-
thetic polymers and their applications is presented in Table 1.
Electrospinning is a simple and cost-effective method to generate 3D
ﬁber-containing materials. However, due to the need of high electrical
ﬁelds and harsh solvents, it is quite challenging to maintain protein
function. Although there are a few publications focusing on functional
electrospinning of ECM molecules [76], a clinical translation has not
yet been demonstrated.
2.2.3. (Bio)Printing
Printing is a computer-controlled layer-by-layer scaffold fabrication
technique. 3D scaffolds can be produced either by laser-based, printer-
based or nozzle-based printing, whereas the printer-based method is
suitable for printing cells (Fig. 2) [85]. Compared to printing, bioprinting
includes the addition of cells, growth factors or other functional ele-
ments [86]. It has been demonstrated that ECM proteins are suitable
for generating 3D bioprinted scaffolds. Collagens [87], ﬁbrin [88],
decellularized ECM [11] and methacrylated gelatin [89] have been
employed in bioprinting applications. For example, Hoch et al. intro-
duced living chondrocytes to an in-house manufactured gelatin solu-
tion to create a bioink for bioprinting. In their study, the authors
showed that the printed chondrocytes exhibited an excellent viability
[89], concluding that this method is suitable to generate ECM-based
cell carriers for application in cartilage tissue engineering. Due to the
layer-by-layer deposition of the material, complex and well-deﬁned
3D structures, such as whole organs can be realized. Recently, Sun
et al. developed a printing and coating method termed “Patterning on
Topography” (PoT) that enables the layering of proteins such as ﬁbro-
nectin, laminin, collagen type IV, and other ECM proteins onto printed
geometric surfaces ranging from smooth to very topographically com-
plex surfaces with high ﬁdelity [90]. In this method that is elegant inTable 1
Overview of electrospun ECM components and their biomedical applications.
Polymer ECM component
Poly-ε-caprolactone (PCL) Tropoelastin
PCL-gelatin Decorin
Poly(L-lactide-co-ε-caprolactone) Collagen type I
Poly(lactic-co-glycolic acid) (PLGA) Collagen type I
– Collagen type I
Poly(1,8-octanediol citrate) (POC) Collagen type I, decorin, aggr
POC Collagen type III
– Hyaluronic acid; collagen typ
PCL Hyaluronan
PLGA Decellularized ECM
PCL Decellularized ECM
Polydioxanone Decellularized ECM
Polyethylenoxide Collagen I; chondroitin-6-sul
– Laminin(s)its simplicity, thermally sensitive poly(N-isopropylacrylamide) is spin-
coated onto glass coverslips and then sandwiched with ECM proteins
that have been micro-contact printed with a polydimethylsiloxane
stamp. The sandwiched layers are dipped in distilledwater and allowed
to cool to room temperature [90]. This allows the transfer of the printed
ECMprotein layer onto the printed topography layerwhere the ECMad-
heres via hydrophobic interactions, resulting in a highly deﬁned ECM
layered surface that can be used for cell culture or potentially on implant
surfaces. In this work, the printed ECMwas used to elucidate how com-
peting physical and chemical microenvironment cues inﬂuence cardio-
myocyte behavior [90]. Soo et al. performed similar work where their
group used PoT to investigate the effects of ECM patterns on the migra-
tion and differentiation of adult neural stem cells [91]. Using humidiﬁed
micro-contact printing, Ricoult et al. printed ECM proteins onto smooth
surfaces without the need of harsh chemicals that are typically involved
in this process, thus protecting the proteins from denaturalization [92].
They created vascularized printed topographies with nanometerApplication Reference
Vascular graft [139]
Trachea [76]
Tendon [140]
Skeletal muscle [141]
Artery [82]
ecan Artery [82]
Artery [82]
e I Cell growth [142]
Skin [12]
Neural [81]
Cartilage [143]
Fat [144]
fate Tissue regeneration [145]
Cell culture [137]
265S. Hinderer et al. / Advanced Drug Delivery Reviews 97 (2016) 260–269resolution as a proof of principle for the possibility of the solvent-
assisted printing of proteins and nanoparticles [92]. Further options
and current applications of 3D bioprinting in regenerative medicine as
well as current challenges in the ﬁeld including improvement of resolu-
tion, generation of more adequate printable biomaterials and upscaling
to clinical relevant sizes are intensively reviewed by Murphy and Atala
[86]. 3D printed scaffolds have already been used in clinical trials
treating tracheal [93] or craniofacial [94] defects. Although the advan-
tages of ECMmolecules are well known, their introduction to the print-
ing process results in decreased mechanical strengths and thus still
remains challenging [86]. To date, a collagen-basedmaterial has already
been used in a small animal model for wound healing purposes [95];
however, there are no reports on clinically employed bioprinted ECM
scaffolds.
2.2.4. Hydrogels and cell sheets
Hydrogels prepared from natural ECM or ECM components can
either be loaded with drugs or small molecules, or, since they already
contain biochemical information, can be applied alone. Tropoelastin is
an ECM protein that induces several cell responses and which is
known to be non-thrombogenic [96]. Therefore, tropoelastin is a very
promising biomaterial for regenerativemedicine purposes. Under phys-
iological conditions, tropoelastin molecules self-organize into spherical
nanoparticles that coalesce and form a porous hydrogel when adding
crosslinking agents, such as glutaraldehyde [64]. In general, the gelation
process is Ca2+ [97], pH [98] or phosphate [9] dependent or can be in-
duced by light [99] or enzymes [100]. Collagen type I also forms a
solid hydrogelwhen changing the pH [101]. Xu et al. published an inter-
esting study where they attached a tyramine moiety to hyaluronan
[100]. The modiﬁed hyaluronan formed a hydrogel when interacting
with horseradish peroxidase. In an in vitro study the authors showed
that the hydrogel enables the expansion of embryonic stem cells while
maintaining their pluripotent state [100].
Single ECM proteins can be used to form stable hydrogels, but also
whole ECMs have been used as hydrogel scaffolds. For this purpose, tis-
sues such as omentum [102] ormyocardium [103]where decellularized
and the acellularmatrices were then further processed to form a hydro-
gel. After several preclinical feasibility studies [103], themyocardialma-
trix hydrogel is currently considered for clinical trials, since it promotes
functional improvement of the post-infarcted heart [103]. Furthermore,
in situ polymerizing injectable hydrogels like Novocart® Inject are used
routinely to replace cartilage defects [104]. Overall, great progress has
been made in demonstrating the potential of hydrogels either as scaf-
folds for tissue engineering applications or as drug carriers [6].
Another interesting approach to generate ECM-based biomaterials is
the cell sheet technique: Under deﬁned in vitro culture conditions, cells
are instructed to produce their own ECM, resulting in a scaffold-like bio-
material (Fig. 3) [105]. These cell-produced sheets can beused to deliver
cells, drugs as well as proteins to the site of injury in order to initiateFig. 3. Fibroblast-derived ECM sheets. (A) Fibroblast-produced, cell and ECM conregeneration [106]. L'Heureux et al. impressively demonstrated that
ﬁbroblast-derived cell sheets have an adequate strength and thickness
to serve as a tissue-engineered blood vessel [107]. In this study, a
ﬁbroblast-derived cell sheet was produced, rolled up to form a blood
vessel, and decellularized in order to obtain an acellular human-based
ECM-scaffold. The engineered blood vessel was then reseeded with
patient-derived cells [107]. Other cell-produced materials have already
found their way into clinical trials and are currently utilized to support
damaged cornea [108], heart muscle [109] or cartilage [110], or are
used as in vitro-engineered blood vessel substitutes [111]. Interestingly,
it was also suggested that by layering multiple cell sheets, organ devel-
opment could potentially be enabled [112]. Cell sheets nicely resemble
the ECM, but a clear limitation is the time that is needed in order to gen-
erate these materials. Both, cell sheets as well as ECM-based hydrogels
were studied intensely in vitro and have already been successfully ap-
plied in clinical trials.
3. ECM and ECM-like materials as vehicles for safe and targeted cell
and drug delivery
ECM and ECM-like materials have great potential as cell and drug
carriers. A current project supported by the European Union called
AMCARE (Advanced Materials for Cardiac Regeneration) is a great ex-
ample to highlight the relevance and the feasibility of the topic [113].
Themain goal of AMCARE is to improve the function of themyocardium
after myocardial infarction (MI) by developing an injectable hydrogel
for endocardial applications (Cardiogel), and an electrospun patch for
epicardial applications (Cardiopatch). Hyaluronic acid is the main com-
ponent of the hydrogel and patch. These constructs serve as vehicles for
targeted delivery of cardiopoietic cells and growth factors in order to
improve heart function post MI [113]. Skin wound healing has been al-
ready realizedwith ECM-based drug releasing systems [10,114]. For ex-
ample, injecting a collagen hydrogel loaded with micro-RNA 29b into
full thickness wounds in rats, resulted in an improved remodeling of
the skin's ECM [10]. Additionally, a mixture of two ECM proteins –
collagen andhyaluronic acid – has been shown to be a suitable drug car-
rier for skin applications [114]. This ECM-based system demonstrated
the impressive effects on the wound healing capacity when loaded
with antibiotics and growth factors [114]. To date, growth factors
[114,115], antibiotics [114], hydrophobic drugs [116] and inhibitors
[117] have been encapsulated and successfully applied using hyaluronic
acid-based delivery systems. Hyaluronic acid was used as a γ-secretase
inhibitor carrier to treat rheumatoid arthritis [117]. Furthermore,
elastin-like peptides (ELPs) were identiﬁed as an interesting drug carri-
er, since drugs can easily be chemically conjugated [118]. Another ad-
vantage is that ELPs are synthesized from amino acids and therefore
their rate of degradation can be easily programmed [118]. Dreher
et al. generated a temperature responsive ELP doxorubicin conjugate,
which was delivered to solid tumors as a cancer therapy [119]. Intaining sheets in a 6-well plate. (B) ECM sheet after decellularization in PBS.
Fig. 4. Principle of coaxial electrospinning. The inner needle contains a solution of the
functionalmolecule (green), whereas the outer needle is ﬁlledwith a degradable polymer
(black). The resulting ﬁber has a core and a degradable sheath. As soon as the sheath
degrades, the functional molecules release to the surrounding extracellular space.
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used as cell carriers [89,120–122]. A multitude of ECM and ECM-like
materials are used in the ﬁeld of cartilage engineering [89,118,123].
For cartilage applications, chondrocytes have been encapsulated into
hydrogels in order to enable an autologous chondrocyte transplanta-
tion. Products like the hyaluronic acid-based Novocart® 3D and Inject
[104,123] or the ﬁbrin-containing Chondron™ [124] have already
been considered in clinics. Another suitable biomaterial is collagen,
which has been shown to have a great potential when aiming to deliver
mesenchymal stem cells for bone repair [120]. Furthermore, the
strength of collagen as a skin substitute with autologous cells has al-
ready been described in detail [2,125]. An interesting approach for
targeted cell delivery is the use of hyaluronic acid [121,122]. Injectable
thermoreversible hyaluronan-based hydrogels have been developed
to host nucleus pulposus cells [121]. Hyaluronan-based hydrogels can
be produced as shear-thinning hydrogels [122]. Gaffey et al. developed
a promising system where endothelial progenitor cells were delivered
to the infarcted myocardium using hyaluronan-based shear-thinning
system [122]. This methodology enabled direct cell delivery and cell re-
tention in order to enhance vasculogenesis and improve myocardial
function [122]. In our opinion, the immobilization of cells and drugs
on carriers is important in order to enable a precise and targeted appli-
cation as well as a controlled release over time. Using ECMmolecules to
design these carriers results in a potentiallymechanicallyweaker but bi-
ologically more relevant and biocompatible system.
4. Electrospun release systems for cancer therapy
Electrospun scaffolds from synthetic polymers, natural proteins or
hybrid materials are frequently utilized to generate drug-eluting sys-
tems [74]. In the following section, we aimed to highlight the potential
for local applications of chemotherapeutics via electrospun scaffolds. A
simple way to enable bioactive molecule release is to perform scaffold
coating, as discussed in a previous section of this review article. Com-
pared to ﬂat membranes, electrospun scaffolds have the advantage of
an enlarged surface area due to the ﬁbrous structure [126,127]. In this
case, more proteins, growth factors or drugs can be delivered to the re-
gion of interest. Another approach is the direct electrospinning of bioac-
tive substances, which are then present on the ﬁber surface and within
the ﬁber [76,128]. A release can then be realized using degradable poly-
mers like PCL, polyethylene oxide (PEO) or poly(lactic-co-glycolic) acid
(PLGA) [76,129,130]. This technique has already been demonstrated by
electrospinning an emulsion of aqueous decorin with PCL [76]. In this
study, the proteoglycan decorin was still functional after the
electrospinning process [76], and as decorin is known for its anti-
angiogenic properties [15], this substrate could potentially be used for
tumor suppression purposes. A sustained drug release and tumor
growth inhibition was also shown with an electrospun scaffold pre-
pared from a solution containing PLGA and the mitotic inhibitor drug
paclitaxel [126]. Using the same degradable polymer for electro-
spinning, Sampath et al. intensively studied release proﬁles of curcumin,
which is described to be favorable for carcinoma treatment [129].More-
over, the anticancer drug doxorubicin was successfully electrospun as a
multicomponent hybrid including PEO, chitosan and graphite oxide
[130].
In addition to coating or direct electrospinning, there is a third
method named coaxial electrospinning to encapsulate drugs [75]. For
a coaxial set-up, a needle-in-needle construction, as well as two injec-
tion pumps are required [131]. The inner needle is then perfused with
the bioactive agent, whereas the outer needle contains the solution of
a degradable polymer (Fig. 4) [131,132]. The resulting ﬁbers are called
core-sheath ﬁbers [131]. As soon as the polymer degrades, the sheath
gets porous and the drug elutes to the surrounding space. This set-up
has been used to provide drug delivery systems for cancer therapies
[131]. Doxorubicin, for example, was encapsulated in a polyvinyl alco-
hol/chitosan sheath [131]. In another study the same drug was coaxialelectrospun using crosslinked gelatin as the sheath. Here, the doxorubi-
cin was delivered as micelles. Therefore, doxorubicin-PCL-PEG micelles
were assembledﬁrst, followedby coaxial electrospinning [133]. To date,
there is no electrospun release system that is clinically approved and ap-
plied for cancer treatment; however, there are many interesting, suc-
cessful and promising in vivo and in vitro studies, indicating the
enormous potential of electrospun biomaterials as drug delivery sys-
tems for cancer therapies.
5. ECM-mimics
The ECM provides chemical, physical and biological cues affecting
cellular function as a result of signal transduction via cell surface recep-
tors [14]. A new and promising approach is to produce scaffolds that
mimic the mechanical and biophysical properties of the ECM. The
ECM is considered as a natural scaffold or biomaterial, which needs to
be precisely analyzed and imitated in order to generate functional scaf-
folds for regenerative medicine or drug delivery applications [134]. The
native ECM is a reservoir for biochemical signals, undergoing perma-
nent remodeling processes [135]. It is well known that cells respond
to biochemical and biophysical cues; however, the synergistic and an-
tagonistic relationship between them and other events taking place in
the ECM is not completely understood [135] and is therefore quite chal-
lenging to mimic. The structure and architecture of a native heart valve
wasmimicked using electrospinning as a ﬁber forming technique [4]. In
this study, the authors also identiﬁedmechanical characteristics such as
Young's modulus, tensile strength, expansion and water uptake capaci-
ty, and designed a scaffold based on these values [4]. In a similar study, a
scaffold was generated tomimicki themechanical properties of adipose
tissue [136]. Today, many concepts exist to additionally include biolog-
ical cues. Neal et al. mimicked the morphological and biological proper-
ties of the basement membrane by producing a laminin ﬁber network
[137]. Another way to introduce biological information is speciﬁc sur-
face modiﬁcation, such as ECM-inspired coatings [69,138].
The ECM is a highly complex network that varies in its composition
from tissue to tissue and organ to organ. Although it is clearly not easy to
resemble all facets of the ECM, different studies demonstrated that it is
important to get inspired by the native ECMwhen aiming for the design
of biomaterial-composed scaffolds. By mimicking the natural ECM, it is
possible to control physical and mechanical properties, as well as cell
growth or drug release, which is an important step towards smart im-
plants with a regenerative potential.
6. Conclusion
ECM and ECM-like materials have a great potential to serve as natu-
ral or nature-mimicking scaffolds in the ﬁeld of regenerative medicine.
Many studies have successfully demonstrated that these materials can
be used as vehicles to deliver cells and drugs to the human body. Com-
pared to ECM biomaterials, synthetic polymers are more favorable in
terms of mechanical loading as well as reproducibility, since their syn-
thesis can be easily controlled. Another beneﬁt of synthetic biomaterials
is the ability of producing cost-efﬁcient carriers. However, despite these
267S. Hinderer et al. / Advanced Drug Delivery Reviews 97 (2016) 260–269considerable advantages, there is a great interest in the utilization of
ECM and ECM-like biomaterials as potential cell and drug carriers, pro-
moted by an unmet need of fully functional and biocompatible mate-
rials. Synthetic polymers are inert and in most cases do not sufﬁciently
interact with the surrounding cells. In order to address functionality,
biocompatibility and material integration to the tissue, a more physio-
logical microenvironment needs to be created by using, for example,
ECM molecules. By utilizing these highly functional materials, the in-
duction of tissue or organ remodeling and regeneration is possible. Fur-
thermore, these superior biomaterials have already been investigated
for cancer treatment, forwhich they seem to be promising drug delivery
vehicles. Although most of the approaches discussed in this review re-
ﬂect proof-of-principal or animal studies, research teams all over the
world areworking to translate these accomplishments into clinical real-
ity in order to provide safer transplants and implants, improve cell and
drug delivery strategies, and design more efﬁcient cancer therapies.Acknowledgments
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